14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days £0.180 £0.240 Monday, 15th Apr 2024 NFX.L stock ended at £0.205. This is 7.27% more than the trading day before Friday, 12th Apr 2024. During the day the stock fluctuated 27.78% from a day low at £0.180 to a day high of £0.230.
90 days £0.180 £0.440
52 weeks £0.180 £0.440

Historical Newfield Exploration Company prices

Date Open High Low Close Volume
2024-04-15 £0.180 £0.230 £0.180 £0.205 477 838
2024-04-12 £0.230 £0.230 £0.191 £0.191 554 338
2024-04-11 £0.189 £0.206 £0.188 £0.205 279 047
2024-04-10 £0.230 £0.230 £0.180 £0.205 10 201
2024-04-09 £0.206 £0.230 £0.188 £0.230 406 258
2024-04-08 £0.180 £0.230 £0.180 £0.205 3 541 653
2024-04-05 £0.180 £0.230 £0.180 £0.187 920 376
2024-04-04 £0.186 £0.230 £0.186 £0.205 902 397
2024-04-03 £0.194 £0.200 £0.190 £0.190 1 271 734
2024-04-02 £0.190 £0.190 £0.190 £0.190 0
2024-03-28 £0.180 £0.191 £0.180 £0.190 2 110 612
2024-03-27 £0.180 £0.180 £0.180 £0.180 225
2024-03-26 £0.200 £0.200 £0.189 £0.190 2 900 438
2024-03-25 £0.197 £0.197 £0.183 £0.190 1 254 870
2024-03-22 £0.195 £0.198 £0.190 £0.198 3 733 673
2024-03-21 £0.192 £0.192 £0.192 £0.192 0
2024-03-20 £0.211 £0.230 £0.190 £0.192 4 559 135
2024-03-19 £0.200 £0.240 £0.200 £0.220 52 700
2024-03-18 £0.200 £0.210 £0.200 £0.210 803 123
2024-03-15 £0.206 £0.212 £0.201 £0.201 575 088
2024-03-14 £0.200 £0.220 £0.200 £0.220 156 132
2024-03-13 £0.212 £0.240 £0.212 £0.220 102 503
2024-03-12 £0.212 £0.220 £0.200 £0.210 819 524
2024-03-11 £0.205 £0.230 £0.200 £0.220 2 291 112
2024-03-08 £0.205 £0.220 £0.205 £0.210 705 780
Click to get the best stock tips daily for free!

About Newfield Exploration Company

Newfield Exploration Company Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. Its lead programs include NXP001, which is in Phase 1-ready stage for oncology supportive care; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. The company is also developing NXP004, which is in the research Phase for treating oncology. It also has an optio... NFX.L Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT